AB018. Management of recurrent thymic malignancies after thymectomy: delayed treatment and long-term survival
Mediastinum · 2026-10 · 10 · AB018-AB018
DOI: 10.21037/med-26-ab018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediastinum, 2026-10. Verfasst von Nassrene Y. Elmadhun und 2 weiteren Autor:innen.
Abstract (Originalsprache)
BACKGROUND: Thymic malignancies are rare tumors that are primarily treated surgically and often follow an indolent course, even after recurrence. While treatment of recurrence including surgery has been shown to improve outcomes, data describing treatment patterns and long-term outcomes after recurrence remains limited. We sought to investigate management strategies and outcomes for recurrent thymic malignancies within an integrated healthcare system. METHODS: We performed a retrospective cohort study of patients who developed recurrence after resection for thymic malignancy within an integrated regional healthcare system between 2007–2023. Patient demographics, histology, Masaoka stage, and margin status at the index resection were analyzed. Patients with recurrence within 3 months after surgery were excluded. RESULTS: Among 335 patients undergoing thymectomy for thymic malignancy, 31 (9.2%) developed recurrence, including 9 (29%) with thymic carcinoma. The median age at the time of surgery was 59 years, 14 (45%) were female and complete resection was achieved in 15 (48%). Median follow-up was 68.2 months. Most recurrences (27, 87%) were detected through surveillance imaging in asymptomatic patients. Recurrences involved the mediastinum (2, 6%), pleura (22, 71%), lung (2, 6%), and distant sites (6, 19%). Fourteen patients (45%) underwent surgical resection of recurrent disease. Median time to recurrence was 34.7 months with the longest observed recurrence at 99.1 months. Median time from detection of recurrence to treatment was 2.7 months, although 10 (31%) either delayed treatment for more than 6 months (6, 19%) or declined treatment altogether (4, 13%). Among these 10 patients, only one patient who delayed treatment by 1 year died. Median survival from detection of recurrence was 60 months, with survival of 56% at 5 years and 20% at 10 years. CONCLUSIONS: Recurrence after resection of thymic malignancy is predominantly identified through surveillance imaging and often follows a prolonged asymptomatic clinical course. Nearly one-third of patients with recurrence who delayed or declined treatment demonstrated favorable outcomes, underscoring the indolent nature of thymic malignancies and possibility of lead time bias within outcomes. These findings support individualized management and shared decision-making when recurrence is identified.
Zitieren
APA
Elmadhun, N. Y., Choe, G., & Vasic, I. (2026). AB018. Management of recurrent thymic malignancies after thymectomy: delayed treatment and long-term survival. Mediastinum, 10, AB018-AB018. https://doi.org/10.21037/med-26-ab018
Vancouver
Elmadhun NY, Choe G, Vasic I. AB018. Management of recurrent thymic malignancies after thymectomy: delayed treatment and long-term survival. Mediastinum. 2026;10:AB018-AB018. doi:10.21037/med-26-ab018
BibTeX
@article{Elmadhun2026,
author = {Elmadhun, Nassrene Y. and Choe, Giye and Vasic, Ivana},
title = {AB018. Management of recurrent thymic malignancies after thymectomy: delayed treatment and long-term survival},
journal = {Mediastinum},
year = {2026},
volume = {10},
pages = {AB018--AB018},
doi = {10.21037/med-26-ab018}
}
EUVIMED